GS1-144

DRUG2 trials

Sponsors

Changchun GeneScience Pharmaceutical Co., Ltd.

Conditions

Adult Healthy VolunteersVasomotor SymptomsVasomotor Syndrome

Phase 1

A Study to Assess Safety and Tolerability of GS1-144 in Healthy Volunteers

CompletedNCT06204250

Changchun GeneScience Pharmaceutical Co., Ltd.Adult Healthy Volunteers, Vasomotor Symptoms

Start: 2024-02-27End: 2024-12-19Updated: 2025-02-17

Phase 2

Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women.

CompletedNCT06726850

Changchun GeneScience Pharmaceutical Co., Ltd.Vasomotor Syndrome

Start: 2024-10-14End: 2025-07-29Updated: 2026-04-29